These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 27761809)

  • 1. Detection of Autophagy Induction After HDAC Inhibitor Treatment in Leukemic Cells.
    Göder A; Mahendrarajah N; Krämer OH
    Methods Mol Biol; 2017; 1510():3-10. PubMed ID: 27761809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phospho-Flow Analysis of Primary Mouse Cells After HDAC Inhibitor Treatment.
    Hildebrand D; Kubatzky KF
    Methods Mol Biol; 2017; 1510():233-243. PubMed ID: 27761825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of HDACi-Induced Protein Cleavage by Caspases.
    Treude F; Gladbach T; Plaster J; Hartkamp J
    Methods Mol Biol; 2017; 1510():11-22. PubMed ID: 27761810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations.
    Rivera-Del Valle N; Cheng T; Irwin ME; Donnella H; Singh MM; Chandra J
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):483-495. PubMed ID: 29313067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of HDACi-Induced Cytotoxicity.
    Marx-Blümel L; Marx C; Kühne M; Sonnemann J
    Methods Mol Biol; 2017; 1510():23-45. PubMed ID: 27761811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation.
    Borbone E; Berlingieri MT; De Bellis F; Nebbioso A; Chiappetta G; Mai A; Altucci L; Fusco A
    Oncogene; 2010 Jan; 29(1):105-16. PubMed ID: 19802013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential regulation of Bdnf expression in cortical neurons by class-selective histone deacetylase inhibitors.
    Koppel I; Timmusk T
    Neuropharmacology; 2013 Dec; 75():106-15. PubMed ID: 23916482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ginsenoside 20(s)-Rh2 as potent natural histone deacetylase inhibitors suppressing the growth of human leukemia cells.
    Liu ZH; Li J; Xia J; Jiang R; Zuo GW; Li XP; Chen Y; Xiong W; Chen DL
    Chem Biol Interact; 2015 Dec; 242():227-34. PubMed ID: 26482938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone Deacetylase Inhibitors Promote Mitochondrial Reactive Oxygen Species Production and Bacterial Clearance by Human Macrophages.
    Ariffin JK; das Gupta K; Kapetanovic R; Iyer A; Reid RC; Fairlie DP; Sweet MJ
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1521-9. PubMed ID: 26711769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of HDACi on Immunological Functions.
    Winkler R; Kosan C
    Methods Mol Biol; 2017; 1510():93-101. PubMed ID: 27761815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitor pharmacodynamic analysis by multiparameter flow cytometry.
    Chung EJ; Lee S; Sausville EA; Ryan Q; Karp JE; Gojo I; Telford WG; Lee MJ; Kong HS; Trepel JB
    Ann Clin Lab Sci; 2005; 35(4):397-406. PubMed ID: 16254255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic Targeting of Autophagy via HDAC Inhibition in Tumor Cells: Role of p53.
    Mrakovcic M; Bohner L; Hanisch M; Fröhlich LF
    Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitors of histone deacetylases in class I and class II suppress human osteoclasts in vitro.
    Cantley MD; Fairlie DP; Bartold PM; Rainsford KD; Le GT; Lucke AJ; Holding CA; Haynes DR
    J Cell Physiol; 2011 Dec; 226(12):3233-41. PubMed ID: 21344383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MS-275 inhibits aroclor 1254-induced SH-SY5Y neuronal cell toxicity by preventing the formation of the HDAC3/REST complex on the synapsin-1 promoter.
    Formisano L; Guida N; Laudati G; Mascolo L; Di Renzo G; Canzoniero LM
    J Pharmacol Exp Ther; 2015 Feb; 352(2):236-43. PubMed ID: 25467131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and evaluation of antiestrogen and histone deacetylase inhibitor molecular hybrids.
    Mendoza-Sanchez R; Cotnoir-White D; Kulpa J; Jutras I; Pottel J; Moitessier N; Mader S; Gleason JL
    Bioorg Med Chem; 2015 Dec; 23(24):7597-606. PubMed ID: 26613635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experimental study on inhibitory effects of histone deacetylase inhibitor MS-275 and TSA on bladder cancer cells.
    Qu W; Kang YD; Zhou MS; Fu LL; Hua ZH; Wang LM
    Urol Oncol; 2010; 28(6):648-54. PubMed ID: 19181544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1.
    Rosato RR; Almenara JA; Grant S
    Cancer Res; 2003 Jul; 63(13):3637-45. PubMed ID: 12839953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells.
    Nishioka C; Ikezoe T; Yang J; Takeuchi S; Koeffler HP; Yokoyama A
    Leuk Res; 2008 Sep; 32(9):1382-92. PubMed ID: 18394702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of histone deacetylase1 induces autophagy.
    Oh M; Choi IK; Kwon HJ
    Biochem Biophys Res Commun; 2008 May; 369(4):1179-83. PubMed ID: 18342621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.